

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
31 January 2008 (31.01.2008)

PCT

(10) International Publication Number  
**WO 2008/014457 A1**

- (51) International Patent Classification:  
A61P 27/02 (2006.01) A61K 31/165 (2006.01)
- (21) International Application Number:  
PCT/US2007/074603
- (22) International Filing Date: 27 July 2007 (27.07.2007)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:  
60/820,735 28 July 2006 (28.07.2006) US
- (71) Applicant (for all designated States except US): **ALCON MANUFACTURING, LTD.** [US/US]; 6201 S. Freeway, Fort Worth, Texas 76134-2099 (US).

John [US/US]; 2821 Donnybrook Drive, Burleson, Texas 76028 (US).

(74) Agents: **SCHULTZ, Teresa J.** et al.; Alcon Research, LTD., IP Legal, Mail Code TB4-8, 6201 South Freeway, Fort Worth, Texas 76134-2099 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.


- (72) Inventors; and
- (75) Inventors/Applicants (for US only): **COLLIER JR., Robert** [US/US]; 3701 Big Bear Lake Drive, Arlington, Texas 76016 (US). **KAPIN, Michael** [US/US]; 3602 Silkwood Trail, Arlington, Texas 76016 (US). **YANNI,**

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,

[Continued on next page]

(54) Title: MONOAMINE OXIDASE INHIBITORS USEFUL FOR TREATING DISORDERS OF THE OUTER RETINA

Prevention of Retinal Lesions by Treatment with Sildenafil



\* Significantly different from vehicle (p <0.05) and not different from control (p >0.05)

(57) Abstract: Compositions and methods for treating disorders of the outer retina with compounds that inhibit monoamine oxidase are disclosed.

WO 2008/014457 A1



FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL,  
PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM,  
GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

— *before the expiration of the time limit for amending the  
claims and to be republished in the event of receipt of  
amendments*

**Published:**

— *with international search report*

*For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.*

## MONOAMINE OXIDASE INHIBITORS USEFUL FOR TREATING DISORDERS OF THE OUTER RETINA

### BACKGROUND OF THE INVENTION

5

#### 1. Field of Invention

The present invention is directed to compounds which are inhibitors of monoamine oxidase and their use in treating disorders of the outer retina resulting from acute or chronic degenerative conditions or diseases of the eye.

10

#### 2. Description of Related Art

Age-related macular degeneration (AMD) is the leading cause of blindness in the elderly, with an incidence of about 20% in adults 65 years of age increasing to 37% in individuals 75 years or older. Non-exudative AMD is characterized by drusen accumulation and atrophy of rod and cone photoreceptors in the outer retina, retinal pigment epithelium (RPE), Bruch's membrane and choriocapillaris; while exudative AMD leads to choroidal neovascularization (Green and Enger, *Ophthalmol*, 100:1519-35, 1993; Green et al., *Ophthalmol*, 92:615-27, 1985; Green and Key, *Trans Am Ophthalmol Soc*, 75:180-254, 1977; Bressler et al., *Retina*, 14:130-42, 1994; Schneider et al., *Retina*, 18:242-50, 1998; Green and Kuchle (1997). In: Yannuzzi, L.A., Flower, R.W., Slakter, J.S. (Eds.) *Indocyanine green angiography*. St. Louis: Mosby, p. 151-6). Retinitis pigmentosa (RP) represents a group of hereditary dystrophies characterized by rod degeneration with secondary atrophy of cone photoreceptors and underlying pigment epithelium. (Pruett, *Trans Am Ophthalmol Soc*, 81:693-735, 1983; Heckenlively, *Trans Am Ophthalmol Soc*, 85:438-470, 1987; Pagon, *Sur Ophthalmol*, 33:137-177, 1988; Berson, *Invest Ophthalmol Vis Sci*, 34:1659-1676, 1993; Nickells and Zack, *Ophthalmic Genet*, 17:145-65, 1996). The pathogenesis of retinal degenerative diseases, such as AMD and RP, is multifaceted and can be triggered by environmental factors in normal individuals or in those who are genetically predisposed. To date more than 100 genes have been mapped or cloned that may be associated with various outer retinal degenerations.

25

30

Light exposure is an environmental factor that has been identified as a contributing factor to the progression of retinal degenerative disorders such as AMD (Young, *Sur Ophthalmol*, 32:252-269, 1988; Taylor, et al., *Arch Ophthalmol*, 110:99-104, 1992; Cruickshank, et al., *Arch Ophthalmol*, 111:514-518, 1993). Photo-oxidative stress leading to light damage to retinal cells has been shown to be a useful model for studying retinal degenerative diseases for the following reasons: damage is primarily to the photoreceptors and retinal pigment epithelium (RPE) of the outer retina, the same cells that are affected in hereditary degenerative diseases (Noell et al., *Invest Ophthalmol Vis Sci*, 5, 450-472, 1966; Bressler et al., *Sur Ophthalmol*, 32, 375-413, 1988; Curcio et al., *Invest Ophthalmol Vis Sci*, 37, 1236-1249, 1996); apoptosis is the cell death mechanism by which photoreceptor and RPE cells are lost in AMD and RP, as well as following a photo-oxidative induced cell injury (Ge-Zhi et al., *Trans AM Ophthalmol Soc*, 94, 411-430, 1996; Abler et al., *Res Commun Mol Pathol Pharmacol*, 92, 177-189, 1996; Nickells and Zack, *Ophthalmic Genet*, 17:145-65, 1996); light has been implicated as an environmental risk factor for progression of AMD and RP (Taylor et al., *Arch Ophthalmol*, 110, 99-104, 1992; Naash et al., *Invest Ophthalmol Vis Sci*, 37, 775-782, 1996); and therapeutic interventions which inhibit photo-oxidative injury have also been shown to be effective in animal models of hereditary degenerative retinal disease (LaVail et al., *Proc Nat Acad Sci*, 89, 11249-11253, 1992; Fakforovich et al., *Nature*, 347, 83-86, 1990; Frasson et al., *Nat. Med.* 5, 1183-1187, 1990).

A number of different compound classes have been identified in various animal models that minimize retinal photo-oxidative injury. They include: antioxidants such as ascorbate (Organisciak et al., *Invest Ophthalmol Vis Sci*, 26:1589-1598, 1985), dimethylthiourea (Organisciak et al., *Invest Ophthalmol Vis Sci*, 33:1599-1609, 1992; Lam et al., *Arch Ophthalmol*, 108:1751-1752, 1990),  $\alpha$ -tocopherol (Kozaki et al., *Nippon Ganka Gakkai Zasshi*, 98:948-954, 1994) and  $\beta$ -carotene (Rapp et al., *Cur Eye Res*, 15:219-232, 1995); calcium antagonists such as flunarizine (Li et al., *Exp Eye Res*, 56: 71-78, 1993; Edward et al., *Arch Ophthalmol*, 109, 554-622, 1992; Collier et al., *Invest Ophthalmol Vis Sci*, 36:S516); growth factors such as basic-fibroblast growth factor, brain derived nerve factor, ciliary neurotrophic factor, and interleukin-1- $\beta$  (LaVail et al., *Proc Nat Acad Sci*, 89, 11249-11253, 1992); glucocorticoids such as methylprednisolone (Lam et al., *Graefes Arch Clin Exp Ophthalmol*, 231, 729-736, 1993) and dexamethasone (Fu et al., *Exp Eye Res*,

54, 583-594, 1992); iron chelators such as desferrioxamine (Li et al., *Cur Eye Res*, 2, 133-144, 1991); NMDA-antagonists such as eliprodil and MK-801 (Collier et al., *Invest Ophthal Vis Sci*, 40:S159, 1999).

5 Monoamine oxidase (MAO) inhibitors have been shown to inhibit induction of apoptosis. This inhibition is thought to result from altering gene expression for the scavenger proteins Cu/Zn superoxide dismutase (SOD1) and MN superoxide dismutase (SOD2) as well as the onco-genes Bcl-2, Bcl-<sub>XL</sub>, Bax, nitric oxide synthase, c-JUN and nicotinamide adenine dinucleotide dehydrogenase. Rasagiline (1 mg/kg), a MAO-B  
10 inhibitor, has been shown to significantly accelerate the recovery of motor function and spatial memory in a mouse closed head injury model. Additionally, cerebral edema was reduced 40-50%. Certain other MAO inhibitors have been described for other disorders. In the retina, the MAO inhibitors selegiline and desmethylselegiline have been shown to protect ganglion cells from NMDA-induced excitotoxicity (Takahata et al., *Eur J  
15 Pharmacol*, 458(1-2):81-9, 2003). Deprenyl has also been shown to protect ganglion cells following optic nerve crush (Buys et al., *Cur Eye Res*, 14(2):119-126, 1995) or serum deprivation (Ragaiey et al., *J Ocul Pharmacol Ther*, 13(5):479-88, 1997). The effect of clorgyline, a MAO-A inhibitor, on photoreceptor rhythms of disk shedding and autophagic degradation has been reported (Reme et al., *Trans Ophthalmol Soc U K*, 103 ( Pt 4):405-  
20 10, 1983.).

U.S. Patent 5,263,957 describes N-phenylalkyl substituted  $\alpha$ -amino carboxamide derivatives. The compounds described are said to be useful as antiepileptic, anti-Parkinson, neuroprotective, antidepressant, antispastic, and/or hypnotic agents. The '957  
25 patent does not mention the use of such compounds for treating disorders of the outer retina. In fact, ophthalmic indications are not mentioned at all.

U.S. Patent No. 5,945,454 describes 2-(4-substituted)-benzylamino-2-methylpropanamides and their use as therapeutic agents. The compounds are described as being  
30 active on the central nervous system and are suggested for use in disorders of the central nervous system, including ocular damage or retinopathy. Significantly, the compounds of

this invention are not encompassed within the compounds claimed for use in the described methods.

U.S. Patent No. 5,242,950 describes a method for treating macular degeneration by administering L-deprenyl or a salt thereof. L-deprenyl is a selective MAO-B inhibitor. The L-deprenyl is to be administered orally or transdermally. The '950 patent does not suggest the use of other types of MAO inhibitors, nor does it suggest delivery methods other than oral or transdermal. U.S. Patent No. 5,981,598 describes a method for treating glaucoma by administering a deprenyl compound. The compounds disclosed for use in the methods of the '598 patent or the '950 patent differ significantly from the compounds of this invention. In fact, "deprenyl compound" is defined in the '598 patent as "deprenyl compounds which are structurally similar to deprenyl," thus excluding the preferred compounds of the invention.

WO 2005/039591 describes benzazepine derivatives, which are MAO-B inhibitors. The compounds described therein, again, differ significantly from the compounds of this invention.

None of the above-described publications mention the use of the compounds of this invention to inhibit or prevent retinal degeneration resulting from loss or damage to photoreceptors and/or retinal pigment epithelium cells. What is needed are more effective compounds and methods of treatment for these serious, sight-threatening disorders.

## SUMMARY OF THE INVENTION

The present invention is directed to MAO-A/B and B inhibitors which have been discovered to be useful in treating disorders of the outer retina, particularly: AMD; RP and other forms of hereditary degenerative retinal disease; retinal detachment and tears; macular pucker; ischemia affecting the outer retina; diabetic retinopathy; damage associated with laser therapy (grid, focal, and panretinal) including photodynamic therapy (PDT); trauma; surgical (retinal translocation, subretinal surgery, or vitrectomy) or light-induced iatrogenic retinopathy; and preservation of retinal transplants. As used herein, the outer retina

includes the RPE, photoreceptors, Muller cells (to the extent that their processes extend into the outer retina), and the outer plexiform layer. The compounds are formulated for systemic or local ocular delivery.

5

## BRIEF DESCRIPTION OF THE DRAWINGS

10

The following drawings form part of the present specification and are included to further demonstrate certain aspects of the present invention. The invention may be better understood by reference to these drawings in combination with the detailed description of specific embodiments presented herein.

15

**FIG. 1A and FIG. 1B** show the preservation of the ERG function at 5 days (FIG. 1A) and 1 month (FIG. 1B) in rats dosed systemically with safinamide and exposed to a severe photo-oxidative insult. Dosing of 15-60 mg/kg safinamide provided significant and complete retinal function protection.

**FIG. 2** shows the prevention of retinal lesions by treatment with safinamide. Rats dosed with 60 mg/kg of safinamide were devoid of significant retinal lesions.


20

## DESCRIPTION OF THE INVENTION

### Chemical part

Object of the present invention are compounds of the general formula I

25



I

wherein:

R<sup>1</sup> is C5-C7 cycloalkyl; phenyl (unsubstituted) or phenyl substituted independently with one or more halogens or CF<sub>3</sub>

R<sup>2</sup> is H, C1-C3 alkyl

R<sup>3</sup> is H, C1-C3 alkyl (unsubstituted) or C1-C3 alkyl substituted with OR<sup>6</sup>

5 R<sup>4</sup>, R<sup>5</sup> are, independently H, C1-C3 alkyl

R<sup>6</sup> is H, C1-C2 alkyl

Preferred compounds of formula I are compounds wherein:

10

R<sup>1</sup> is C5-C7 cycloalkyl; phenyl (unsubstituted) or phenyl substituted independently with one or two F, Cl or CF<sub>3</sub>

R<sup>2</sup> is H, C1-C2 alkyl

R<sup>3</sup> is H, C1-C2 alkyl (unsubstituted) or C1-C2 alkyl substituted with OR<sup>6</sup>

15 R<sup>4</sup>, R<sup>5</sup> are independently H, C1-C2 alkyl

R<sup>6</sup> is H, C1-C2 alkyl

More preferred compounds of formula I are compounds wherein:

20

R<sup>1</sup> is phenyl (unsubstituted) or phenyl substituted independently with one or two F, Cl

R<sup>2</sup> is H, CH<sub>3</sub>

R<sup>3</sup> is H, C1-C2 alkyl (unsubstituted) or C1-C2 alkyl substituted with OR<sup>6</sup>

R<sup>4</sup>, R<sup>5</sup> are independently H, CH<sub>3</sub>

25 R<sup>6</sup> is H, CH<sub>3</sub>

Most preferred compounds of formula I are the (S) and (R) compounds wherein:

30 R<sup>1</sup> is 3-fluorophenyl

R<sup>2</sup> is H

R<sup>3</sup> is CH<sub>3</sub>

R<sup>4</sup>, R<sup>5</sup> are H

35 and particularly the (S)-isomer (safinamide).

The compounds of formula I are known compounds and are prepared according to the methods described in US Patent No. 5,263,957.

5 **Biological part**

Retinal diseases are often disruptive to the tissue and can result in a loss of visual function for millions of patients. For example, retinal tissues can be damaged by environmental factors, such as light exposure, which is known to contribute to the  
10 progression of retinal degenerative disorders such as AMD (Young 1988; Taylor *et al.* 1992; Cruickshank *et al.* 1993). To date, no effective treatment exists for neurodegenerative disorders of the retina. Early stages of macular degeneration are typically treated by combinations of antioxidants or anti-inflammatory agents whose efficacy has not been demonstrated in the clinic. Advanced stages of macular degeneration  
15 that lead to severe vision loss are treated either by surgical removal of membranes from the subretinal space, laser photocoagulation, photodynamic therapy, and most recently with VEGF blockers in patients with exudative AMD. No approved treatments are available for the advanced form of dry AMD known as Geographic Atrophy. Laser treatment is also used in the treatment of diabetic retinopathy. It is important to note that both laser  
20 photocoagulation of the retina and surgical excision of subretinal membranes or intravitreal membranes results in the destruction of viable retinal neurons. Prevention or reduction of outer retina damage by MAO inhibitors is a unique and novel therapeutic approach to the management of age-related maculopathy and/or macular degeneration and other retinopathies.

25 In light damage paradigms used by the present inventors, antioxidants were either ineffective ( $\alpha$ -tocopherol) or marginally effective at high doses (ascorbate, vitamin E analogs). Similarly, some calcium antagonists (flunarizine, nicardipine) were moderately effective while others (nifedipine, nimodipine, verapamil) had no effect in preventing light-induced functional or morphological changes. Unexpectedly, it has been discovered  
30 that compounds of this invention are 50 to 100-fold more potent than antioxidants in this light damage paradigm and therefore are useful for treating disorders of the outer retina.

Monoamine oxidase (MAO) is an integral protein of the outer mitochondrial membrane and plays a major role in the inactivation of amines in the central nervous system (CNS) and peripheral nervous system (PNS). In the human CNS, the MAO-A isoenzyme is responsible for deamination of serotonin and noradrenaline, while the MAO-B isoenzyme is responsible for deamination of dopamine. After initial enthusiasm, the use of MAO-A and nonselective MAO inhibitors has been limited by the wide range of MAO induced-drug and MAO induced-food interactions that are possible, particularly with sympathomimetic medications or tyramine-containing foods, resulting in hypertensive reactions. Inhibitors of the MAO-B isoenzyme have demonstrated neuroprotective and neurorescuing properties in a number of models, including: monkey and mouse MPTP model, mouse head injury model; facial nerve axotomy in rats; and acute drug-induced dopaminergic motor dysfunction in rodents. Long acting MAO-B inhibitors (deprenyl, selegiline) have also been associated with insomnia, nausea, benign cardiac arrhythmias, dizziness and headache.

The invention contemplates the use of the MAO inhibitor of general formula I or any pharmaceutically acceptable derivative, including pharmaceutically acceptable salts, for treating disorders of the outer retina. The phrase "pharmaceutically acceptable" means the compounds can be safely used for the treatment of diseases of the outer retina. As used herein, the outer retina includes the RPE, photoreceptors, Muller cells (to the extent that their processes extend into the outer retina), and the outer plexiform layer. The compounds are formulated for systemic or local ocular delivery.

While it is contemplated that any short acting inhibitors of MAO A/B and B will be useful in the methods of the present invention, preferred MAO inhibitors are potent, short acting inhibitors of the MAO-B receptor, such as those compounds described specifically herein. Preferred compounds include 2-{[4-(3-Chloro-benzyloxy)-benzyl]-methylamino}-acetamide, (S)-2-[4-(2-Fluoro-benzyloxy)-benzylamino]-propionamide, (S)-2-[4-(4-Fluoro-benzyloxy)-benzylamino]-propionamide, (S)-2-[4-(3-Chloro-benzyloxy)-benzylamino]-propionamide, (R)-2-[4-(3-Chloro-benzyloxy)-benzylamino]-3-hydroxy-propionamide, (S)-2-(4-Cyclohexylmethoxy-benzylamino)-propionamide, (S)-2-[4-(3-Fluoro-benzyloxy)-benzylamino]-3-hydroxy-propionamide, (S)-2-[4-(3-Chloro-benzyloxy)-benzylamino]-3-hydroxy-propionamide, (S)-2-{[4-(3-Chloro-benzyloxy)-

benzyl]-methyl-amino}-propionamide, (S)-2-[4-(3-Fluoro-benzyloxy)-benzylamino]-propionamide (safinamide), (S)-2-[4-(3-Fluoro-benzyloxy)-benzylamino]-propionamide (safinamide) or any pharmaceutically acceptable derivative or analog or salt of these compounds. The most preferred compound for use in the methods described herein is safinamide or any pharmaceutically acceptable derivative, analog or salt thereof.

Disorders of the outer retina encompass acute and chronic environmentally induced (trauma, ischemia, photo-oxidative stress) degenerative conditions of the photoreceptors and RPE cells in normal or genetically predisposed individuals. Such disorders include, but are not limited to, age-related macular degeneration (AMD); retinitis pigmentosa (RP) and other forms of heredodegenerative retinal disease; retinal detachment; tears; macular pucker; ischemia affecting the outer retina; diabetic retinopathy; damage associated with laser therapy (grid, focal and panretinal) including photodynamic therapy (PDT), thermal or cryotherapy; trauma; surgical (retinal translocation, subretinal surgery or vitrectomy) or light induced iatrogenic retinopathy; and preservation of retinal transplants.

The compounds of this invention, which are potent and selective inhibitors of MAO-B ( $IC_{50}$  in the submicromolar-nanomolar range), *in vitro* and *in vivo*, have generally no relevant effect on MAO-A. After oral administration in mice, the compounds behave as potent, short-acting MAO-B inhibitors with full recovery of activity 8-16 hours after administration of a single dose of substance.

The MAO inhibiting activity of compounds useful for the methods of the present invention may be determined using a variety of methods known to the skilled artisan. Method 1 and Method 2, described below are examples of useful assays for determining MAO B inhibiting activity.

#### METHOD 1

##### ***In vitro* MAO-A and MAO-B enzyme activities assay**

##### ***- Membrane preparations (crude mitochondrial fraction)***

Male Wistar rats (Harlan, Italy – 175-200 g) were sacrificed under light anaesthesia and brains were rapidly removed and homogenized in 8 volumes of ice-cold 0.32 M sucrose

buffer containing 0.1 M EDTA, pH 7.4. The crude homogenate was centrifuged at 2220 rpm for 10 minutes at +4 °C and the supernatant recovered. The pellet was homogenized and centrifuged again. The two supernatants were pooled and centrifuged at 9250 rpm for 10 minutes. The pellet was resuspended in fresh buffer and centrifuged at 11250 rpm for 10 minutes at +4°C. The resulting pellet was stored at -80°C.

***- In vitro enzyme activities assay***

The enzyme activities were assessed with a radioenzymatic assay using the substrates <sup>14</sup>C-serotonin (5-HT) and <sup>14</sup>C-phenylethylamine (PEA) for MAO-A and MAO-B, respectively.

The mitochondrial pellet (500 µg protein) was resuspended in 0.1 M phosphate buffer (pH 7.4). 500 µl of the suspension were added to a 50 µl solution of the test compound or buffer, and incubated for 30 min at 37 °C (preincubation) then the substrate (50 µl) was added. The incubation was carried out for 30 minutes at 37°C (<sup>14</sup>C-5-HT, 5 µM) or for 10 minutes at 37°C (<sup>14</sup>C-PEA, 0.5 µM).

The reaction was stopped by adding 0.2 ml of 37% HCl or perchloric acid. After centrifugation, the deaminated metabolites were extracted with 3 ml of diethyl ether (5-HT) or toluene (PEA) and the radioactive organic phase was measured by liquid scintillation spectrometry at 90% efficiency. The amount of neutral and/or acidic metabolites formed as a result of MAO activity was obtained by measuring the radioactivity of the eluate.

The activity of MAO in the sample, corresponding to a percentage of radioactivity compared with the control activity in the absence of the inhibitor, was expressed as nmoles of substrate transformed/mg protein/min.

The drug inhibition curves were obtained from at least eight different concentration points, each in duplicate ( $10^{-10}$  to  $10^{-5}$  M). The IC<sub>50</sub> values (the drug concentration inhibiting 50% of the enzyme activity) were calculated with confidence intervals determined using non linear regression analysis (best fitting aided-computer program).

The procedure described in Method 1 was used to generate the data shown in Table 1.

## METHOD 2

**Ex vivo MAO-B inhibition**

Test compounds were administered orally to male C57BL mice (Harlan, Italy, 25-27 g) at the single dose of 20 mg/Kg. At various time intervals (1, 2, 4, 8 and 24 h), animals were sacrificed, brains removed, cortices dissected out and stored at -80 °C. Crude homogenates (0.5%) were prepared in 0.1 M phosphate buffer (pH 7.4) and were freshly used. MAO-A and MAO-B activity were assessed as described above.

Table 1.

*In vitro* MAO-A and MAO-B inhibition of some compounds of the invention in rat brain mitochondria

<u>COMPOUND</u>	MAO A	MAO B
	IC <sub>50</sub> , μM	
2-{{[4-(3-Chloro-benzyloxy)-benzyl]-methyl-amino}-acetamide	50	0.04
(S)-2-[4-(2-Fluoro-benzyloxy)-benzylamino]-propionamide	228	0.18
(S)-2-[4-(4-Fluoro-benzyloxy)-benzylamino]-propionamide	93	0.06
(S)-2-[4-(3-Chloro-benzyloxy)-benzylamino]-propionamide	114	0.03
(R)-2-[4-(3-Chloro-benzyloxy)-benzylamino]-3-hydroxy-propionamide	>100	0.11
(S)-2-(4-Cyclohexylmethoxy-benzylamino)-propionamide	301	0.03
(S)-2-[4-(3-Fluoro-benzyloxy)-benzylamino]-3-hydroxy-propionamide	100	0.14
(S)-2-[4-(3-Chloro-benzyloxy)-benzylamino]-3-hydroxy-propionamide	84	0.04
(S)-2-{{[4-(3-Chloro-benzyloxy)-benzyl]-methyl-amino}-propionamide	82	0.06
(S)-2-[4-(3-Fluoro-benzyloxy)-benzylamino]-propionamide (safinamide)	584	0.09

METHOD 3**Neuroprotective activity of MAO inhibitors in the rat photo-oxidative induced retinopathy model**

5

10

15

20

25

30

Photic retinopathy results from excessive excitation of the RPE and neuroretina by absorption of visible or near ultraviolet radiation. Lesion severity is dependent upon wavelength, irradiance, exposure duration, species, ocular pigmentation, and age. Damage may result from peroxidation of cellular membranes, inactivation of mitochondrial enzymes such as cytochrome oxidase, and/or increased intracellular calcium. Cellular damage resulting from photo-oxidative stress leads to cell death by apoptosis, (Shahinfar, et al., 1991, *Current Eye Research*, Vol. 10:47-59; Abler, et al., 1994, *Investigative Ophthalmology & Visual Science*, Vol. 35(Suppl):1517). Oxidative stress induced apoptosis has been implicated as a cause of many ocular pathologies, including, iatrogenic retinopathy, macular degeneration, RP and other forms of heredodegenerative disease, ischemic retinopathy, retinal tears, retinal detachment, glaucoma and retinal neovascularization (Chang, et al., 1995, *Archives of Ophthalmology*, Vol. 113:880-886; Portera-Cailliau, et al., 1994, *Proceedings of National Academy of Science (U.S.A.)*, Vol. 91:974-978; Buchi, E. R., 1992, *Experimental Eye Research*, Vol. 55:605-613; Quigley, et al., 1995, *Investigative Ophthalmology & Visual Science*, Vol. 36:774-786). Photic induced retinal damage has been observed in mice (Zigman, et al., 1975, *Investigative Ophthalmology & Visual Science*, Vol. 14:710-713), rats (Noell, et al., 1966, *Investigative Ophthalmology and Visual Science*, Vol. 5:450-473; Kuwabara, et al., 1968, *Archives of Ophthalmology*, Vol. 79:69-78; LaVail, M. M., 1976, *Investigative Ophthalmology & Visual Science*, Vol. 15:64-70), rabbit (Lawwill, T., 1973, *Investigative Ophthalmology & Visual Science*, Vol. 12:45-51), and squirrel (Collier, et al., 1989; In LaVail et al., *Inherited and Environmentally Induced Retinal Degenerations*. Alan R. Liss, Inc., New York; Collier, et al., 1989, *Investigative Ophthalmology & Visual Science*, Vol. 30:631-637), non-human primates (Tso, M. O. M., 1973, *Investigative Ophthalmology & Visual Science*, Vol. 12:17-34; Ham, et al., 1980, *Vision Research*, Vol. 20:1105-1111; Sperling, et al., 1980, *Vision Research*, Vol. 20:1117-1125; Sykes, et al., 1981, *Investigative Ophthalmology & Visual Science*, Vol. 20:425-434; Lawwill, T., 1982, *Transactions of the American Ophthalmology Society*, Vol. 80:517-577), and man

(Marshall, et al., 1975, *British Journal of Ophthalmology*, Vol. 59:610-630; Green, et al., 1991, *American Journal of Ophthalmology*, Vol. 112:520-27). In man, chronic exposure to environmental radiation has also been implicated as a risk factor for ARMD (Young, R. W., 1988, *Survey of Ophthalmology*, Vol. 32:252-269; Taylor, et al., 1992, *Archives of Ophthalmology*, Vol. 110:99-104; Cruickshank, et al., 1993, *Archives of Ophthalmology*, Vol. 111:514-518)

**Prevention of Photo-oxidative injury with Safinamide:** The efficacy of Safinamide, a short acting MAO-B inhibitor, to protect retinal cells against the induction of photochemical lesions by blue-light exposure was assessed by measuring light-induced changes in retinal functioning (electroretinogram (ERG)) and evaluating retinal morphology changes. Significant dose-dependent protection of retinal function was measured in light exposed rats after a 5-day recovery period in rats dosed with Safinamide (5-60 mg/kg). ERGs were not significantly different from normal after a 1-month recovery period in Safinamide dosed rats (15 to 60 mg/kg).

***Subjects.*** Male Sprague Dawley rats were randomly assigned to drug or vehicle experimental groups. Rats receiving vehicle (N=15) or drug treatment (Safinamide: 5 mg/kg, N=10; 15 mg/kg, N=10; 30 mg/kg, N=10; and 60 mg/kg, N=9) were pre-dosed (IP) at 48, 24 and 0 hours prior to a 6-hour light exposure (spectrally filtered blue light (~220 fc)) and 24 and 48 hours after light exposure. Control rats were housed in their home cage under normal cyclic light exposure. Control rats were not dosed with either vehicle or drug.

***Retinal Function Assessment.*** The ERG is a non-invasive clinical measurement of the electrical response of the eye to a flash of light. The a-wave and b-wave are two components of the ERG that are diagnostic of retinal function. The a-wave reflects outer retina function and is generated by interactions between photoreceptor and RPE while the b-wave reflects inner retina function, particularly on-bipolar cells. Although the inner retina is not significantly damaged by this light exposure, the b-wave is depressed due to the lack of photoreceptor input. Changes in the a-wave amplitude or latency are diagnostic of outer retina pathology. The ERG was recorded after a five day recovery period from dark-adapted anesthetized rats (ketamine-HCl, 75 mg/Kg; xylazine, 6 mg/Kg). The eye's

electrical response to a flash of light was elicited by viewing a ganzfeld. ERGs to a series of light flashes increasing in intensity were digitized to analyze temporal characteristics of the waveform and response voltage-log intensity relationship.

5 ***Light Microscopic Assessment of Retinal Lesions.*** Ocular tissues were fixed in a mixture of paraformaldehyde and glutaraldehyde, dehydrated in an ascending ethanol series, embedded in JB-4 plastic resin, and 1 to 1.5-micron thick sections were analyzed using a quantitative computer image analysis system attached to the microscope. Retinal Pigment Epithelium (RPE), Outer Nuclear Layer (ONL) and Inner  
10 Nuclear Layer (INL) thickness as well as the length of inner segments (IS), where mitochondria are located, and outer segments (OS), which contain the light sensitive photopigment, were measured to assess outer retina protection. As the INL is not significantly affected by light exposure, this layer served as an additional control measurement.

15 **Results.** Blue-light exposure to vehicle-dosed rats resulted in a significant reduction in retinal function (ANOVA,  $p < 0.001$ ), as measured by the ERG, when measured 5 days after light exposure (Figure 1A). After blue-light exposure, maximum a-wave response amplitudes were reduced 69% and maximum b-wave response amplitudes were reduced 71% from vehicle-dosed rats. Dosing with Safinamide resulted in dose-dependent  
20 protection of retinal function (FIG. 1A). At all doses evaluated (5 – 60 mg/kg), significant ERG protection was measured compared to vehicle-dosed rats. Maximum ERG a-wave responses from rats dosed with Safinamide (5 mg/kg) were 52% of normal and responses recorded from rats dosed with 15 or 30 mg/kg were greater than 70% of normal. Retinal responses from Safinamide (60 mg/kg) dosed rats were not significantly diminished  
25 compared to control rats that were maintained under normal, dim, visible, cyclic light.

FIG. 1A shows ERG response amplitudes measured 5 days after a 6-hour blue-light exposure. Dosing with Safinamide (5 – 60 mg/kg) provided significant retinal function protection.

30 After an additional 3-week recovery period, evaluation of the flash-induced retinal response (FIG. 1B) demonstrated no significant recovery of ERG responses from vehicle-

5 dosed rats. Evaluation of the ERG response in Safinamide (15 to 60 mg/kg) dosed rats demonstrated normal ERG a- and b-wave function. Light microscopic evaluation of retinas from vehicle-dosed rats demonstrated significant (ANOVA,  $p < 0.001$ ) thinning of the RPE as well as loss of photoreceptor cells and shortening of their inner + outer segment length (FIG. 2). Dose-dependent reduction in retinal lesions were measured in rats dosed with Safinamide. Retinas obtained from rats dosed with Safinamide (15 and 60 mg/kg) demonstrated a thicker RPE compared to vehicle-dosed rats. The ONL was significantly thicker in rats dosed with Safinamide (15 and 60 mg/kg) and photoreceptor segment length was significantly longer (60 mg/kg) compared to vehicle-dosed rats and not significantly different from normal controls. Retinas from rats dosed with Safinamide (60 mg/kg) were devoid of any significant retinal lesions.

15 In general, for degenerative diseases, the compounds of this invention are administered orally with daily dosage of these compounds ranging between about 0.001 and about 500 milligrams. The preferred total daily dose ranges between about 1 and about 100 milligrams. Non-oral administration, such as, intravitreal, topical ocular, transdermal patch, subdermal, parenteral, intraocular, subconjunctival, or retrobulbar or subtenon's injection, trans scleral (including iontophoresis), posterior juxtasclear delivery, or slow release biodegradable polymers or liposomes may require an adjustment of the total daily dose necessary to provide a therapeutically effective amount of the compound. The Compounds can also be delivered in ocular irrigating solutions. Concentrations should range from about 0.001  $\mu\text{M}$  to about 100  $\mu\text{M}$ , preferably about 0.01  $\mu\text{M}$  to about 5  $\mu\text{M}$ .

25 The compounds can be incorporated into various types of ophthalmic formulations for delivery to the eye (e.g., topically, intracamerally, juxtasclearly, or via an implant). They may be combined with ophthalmologically acceptable preservatives, surfactants, viscosity enhancers, gelling agents, penetration enhancers, buffers, sodium chloride, and water to form aqueous, sterile ophthalmic suspensions or solutions or preformed gels or gels formed in situ. Ophthalmic solution formulations may be prepared by dissolving the compound in a physiologically acceptable isotonic aqueous buffer. Further, the ophthalmic solution may include an ophthalmologically acceptable surfactant to assist in

dissolving the compound. The ophthalmic solutions may contain a viscosity enhancer, such as, hydroxymethylcellulose, hydroxyethylcellulose, hydroxypropylmethylcellulose, methylcellulose, polyvinyl-pyrrolidone, or the like, to improve the retention of the formulation in the conjunctival sac. In order to prepare sterile ophthalmic ointment formulations, the active ingredient is combined with a preservative in an appropriate vehicle, such as, mineral oil, liquid lanolin, or white petrolatum. Sterile ophthalmic gel formulations may be prepared by suspending the active ingredient in a hydrophilic base prepared from the combination of, for example, carbopol-940, or the like, according to the published formulations for analogous ophthalmic preparations; preservatives and tonicity agents can be incorporated.

If dosed topically, the compounds are preferably formulated as topical ophthalmic suspensions or solutions, with a pH of about 4 to 8. The Compounds will normally be contained in these formulations in an amount 0.001% to 5% by weight, but preferably in an amount of 0.01% to 2% by weight. Thus, for topical presentation, 1 to 2 drops of these formulations would be delivered to the surface of the eye 1 to 4 times per day according to the discretion of a skilled clinician.

The following examples are included to demonstrate preferred embodiments of the invention. It should be appreciated by those of skill in the art that the techniques disclosed in the examples which follow represent techniques discovered by the inventor to function well in the practice of the invention, and thus can be considered to constitute preferred modes for its practice. However, those of skill in the art should, in light of the present disclosure, appreciate that many changes can be made in the specific embodiments which are disclosed and still obtain a like or similar result without departing from the spirit and scope of the invention.

The following topical ophthalmic formulations are useful according to the present invention administered 1-4 times per day according to the discretion of a skilled clinician.

**EXAMPLE 1**

<b>Ingredients</b>	<b>Amount (wt %)</b>
<b>Safinamide</b>	0.01 – 2%
Hydroxypropyl methylcellulose	0.5%
Dibasic sodium phosphate (anhydrous)	0.2%
Sodium chloride	0.5%
Disodium EDTA (Edetate disodium)	0.01%
Polysorbate 80	0.05%
Benzalkonium chloride	0.01%
Sodium hydroxide / Hydrochloric acid	For adjusting pH to 7.3 – 7.4
Purified water	q.s. to 100%

**EXAMPLE 2**

5

<b>Ingredients</b>	<b>Amount (wt %)</b>
<b>Safinamide</b>	0.01 – 2%
Methyl cellulose	4.0%
Dibasic sodium phosphate (anhydrous)	0.2%
Sodium chloride	0.5%
Disodium EDTA (Edetate disodium)	0.01%
Polysorbate 80	0.05%
Benzalkonium chloride	0.01%
Sodium hydroxide / Hydrochloric acid	For adjusting pH to 7.3 – 7.4
Purified water	q.s. to 100%

**EXAMPLE 3**

<b>Ingredients</b>	<b>Amount (wt %)</b>
Compound	0.01 – 2%
Guar gum	0.4- 6.0%
Dibasic sodium phosphate (anhydrous)	0.2%
Sodium chloride	0.5%
Disodium EDTA (Edetate disodium)	0.01%
Polysorbate 80	0.05%
Benzalkonium chloride	0.01%
Sodium hydroxide / Hydrochloric acid	For adjusting pH to 7.3 – 7.4
Purified water	q.s. to 100%

5

**EXAMPLE 4**

<b>Ingredients</b>	<b>Amount (wt %)</b>
Compound	0.01 – 2%
White petrolatum and mineral oil and lanolin	Ointment consistency
Dibasic sodium phosphate (anhydrous)	0.2%
Sodium chloride	0.5%
Disodium EDTA (Edetate disodium)	0.01%
Polysorbate 80	0.05%
Benzalkonium chloride	0.01%
Sodium hydroxide / Hydrochloric acid	For adjusting pH to 7.3 – 7.4

10

**EXAMPLE 5**

<b>10mM IV Solution w/v%</b>	
<b>Safinamide</b>	0.384% (about 4%)
L-Tartaric acid	2.31%
Sodium hydroxide	pH 3.8
Hydrochloric acid	pH 3.8
Purified water	q.s. 100%

5

**EXAMPLE 6**

<b>5mg Capsules</b>	
<b>Ingredient</b>	<b>mg/capsule (Total Wt. 22a mg)</b>
<b>Safinamide</b>	5
Lactose, anhydrous	55.7
Strach, Sodium carboxy-methyl	8
Cellulose, microcrystalline	30
Colloidal silicon dioxide	.5
Magnesium stearate	.8


10 All of the compositions and/or methods disclosed and claimed herein can be made and executed without undue experimentation in light of the present disclosure. While the compositions and methods of this invention have been described in terms of preferred embodiments, it will be apparent to those of skill in the art that variations may be applied to the compositions and/or methods and in the steps or in the sequence of steps of the method described herein without departing from the concept, spirit and scope of the invention. More specifically, it will be apparent that certain agents which are both  
15 chemically and structurally related may be substituted for the agents described herein to achieve similar results. All such substitutions and modifications apparent to those skilled

in the art are deemed to be within the spirit, scope and concept of the invention as defined by the appended claims.

5 The references cited herein, to the extent that they provide exemplary procedural or other details supplementary to those set forth herein, are specifically incorporated herein by reference.

**We Claim:**

1. A method for treating disorders of the outer retina which comprises administering a composition comprising a therapeutically effective amount of a  
 5 monoamine oxidase inhibitor, wherein said monoamine oxidase inhibitor is a compound of formula I or a pharmaceutically acceptable derivative or analogue thereof



I

10 wherein:

R¹ is C5-C7 cycloalkyl; phenyl (unsubstituted) or phenyl substituted independently with one or more halogens or CF<sub>3</sub>

R² is H, C1-C3 alkyl

15 R³ is H, C1-C3 alkyl (unsubstituted) or C1-C3 alkyl substituted with OR<sup>6</sup>

R⁴, R⁵ are, independently H, C1-C3 alkyl

R⁶ is H, C1-C2 alkyl.

2. The method claim 1 wherein:

20 R¹ is C5-C7 cycloalkyl; phenyl (unsubstituted) or phenyl substituted independently with one or two F, Cl or CF<sub>3</sub>

R² is H, C1-C2 alkyl

R³ is H, C1-C2 alkyl (unsubstituted) or C1-C2 alkyl substituted with OR<sup>6</sup>

R⁴, R⁵ are independently H, C1-C2 alkyl

25 R⁶ is H, C1-C2 alkyl.

3. The method of claim 1 wherein:

R¹ is phenyl (unsubstituted) or phenyl substituted independently with one or two F, Cl

R² is H, CH<sub>3</sub>

R³ is H, C1-C2 alkyl (unsubstituted) or C1-C2 alkyl substituted with OR<sup>6</sup>

30 R⁴, R⁵ are independently H, CH<sub>3</sub>

R⁶ is H, CH<sub>3</sub>.

4. The method of claim 3 wherein:

R<sup>1</sup> is 3-Fluorophenyl

R<sup>2</sup> is H

R<sup>3</sup> is CH<sub>3</sub>

5 R<sup>4</sup>, R<sup>5</sup> are H.

5. The method of claim 4, wherein the compound is safinamide.

6. The method of claim 1 wherein the disorder is selected from the group consisting of: AMD; RP and other forms of hereditary degenerative retinal disease; retinal detachment and tears; macular pucker; ischemia affecting the outer retina; diabetic retinopathy; damage associated with laser therapy (grid, focal, and panretinal) including photodynamic therapy (PDT); trauma; surgical (retinal translocation, subretinal surgery, or vitrectomy) or light-induced iatrogenic retinopathy; and preservation of retinal transplants.

7. The method of claim 6, wherein the disorder is selected from the group consisting of AMD, RP, and diabetic retinopathy.

8. The method of claim 7 wherein the disorder is AMD.


9. The method of claim 1, wherein the amount of monoamine oxidase inhibitor in the composition is from about 0.01 to about 2%.

10. The method of claim 1, wherein the administration is via a method selected from the group consisting of topical ocular administration, intravitreal injection, oral administration, retrobulbar administration, subconjunctival administration, subtenon administration, transdermal administration, intravenous administration, intraperitoneal administration, subcutaneous administration, administration via slow release biodegradable polymers, liposomes, and via mini-pumps.

11. The method of claim 10, wherein the administration is via local delivery.

12. A method of treating or preventing retinal degeneration, said method comprising administering to a patient a composition comprising a therapeutically effective

amount of a monoamine oxidase inhibitor, wherein said monoamine oxidase inhibitor is a compound of formula I, or a pharmaceutically acceptable derivative or analog thereof



I

wherein:

R<sup>1</sup> is C5-C7 cycloalkyl; phenyl (unsubstituted) or phenyl substituted independently with one or more halogens or CF<sub>3</sub>

R<sup>2</sup> is H, C1-C3 alkyl

R<sup>3</sup> is H, C1-C3 alkyl (unsubstituted) or C1-C3 alkyl substituted with OR<sup>6</sup>

R<sup>4</sup>, R<sup>5</sup> are, independently H, C1-C3 alkyl

R<sup>6</sup> is H, C1-C2 alkyl.

13. The method of claim 12, wherein the monoamine oxidase inhibitor is safinamide.

14. The method of claim 12, wherein the disorder is selected from the group consisting of: AMD; RP and other forms of hereditary degenerative retinal disease; retinal detachment and tears; macular pucker; ischemia affecting the outer retina; diabetic retinopathy; damage associated with laser therapy (grid, focal, and panretinal) including photodynamic therapy (PDT); trauma; surgical (retinal translocation, subretinal surgery, or vitrectomy) or light-induced iatrogenic retinopathy; and preservation of retinal transplants.

15. The method of claim 14, wherein the disorder is selected from the group consisting of AMD, RP, and diabetic retinopathy.

16. The method of claim 15, wherein the disorder is AMD.


17. The method of claim 12, wherein the amount of monoamine oxidase inhibitor in the composition is from about 0.01% to about 2%.

18. The method of claim 12, wherein the administration is via a method selected from the group consisting of topical ocular administration, intravitreal injection, oral administration, retrobulbar administration, subconjunctival administration, subtenon  
5 administration, transdermal administration, intravenous administration, intraperitoneal administration, subcutaneous administration, administration via slow release biodegradable polymers, liposomes, and via mini-pumps.

19. The method of claim 18, wherein the administration is via local delivery.

**Prevention of Photic-Induced Retinopathy with Safinamide**

*5-Day Recovery*




\* Significantly higher response compared to vehicle (p<0.05).

\*\* Significantly higher response compared to vehicle (p<0.05) and not different from normal (p>0.05).

**FIG. 1A**

## Prevention of Photic-Induced Retinopathy with Safinamide


*1-Month Recovery*



\*\* Significantly higher response compared to vehicle ( $p < 0.05$ ) and not different from normal ( $p > 0.05$ ).

**FIG. 1B**

**Prevention of Retinal Lesions by Treatment with Safinamide**



\* Significantly different from vehicle ( $p < 0.05$ ) and not different from control ( $p > 0.05$ )

**FIG. 2**

## INTERNATIONAL SEARCH REPORT

International application No  
PCT/US2007/074603A. CLASSIFICATION OF SUBJECT MATTER  
INV. A61P27/02 A61K31/165

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, EMBASE, BIOSIS, CHEM ABS Data

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US 5 242 950 A (FRIES HASTINGS BARBARA A [US]) 7 September 1993 (1993-09-07) cited in the application column 2, line 34 - line 38 column 2, line 50 - line 51 -----	1-19
Y	US 5 236 957 A (DOSTERT PHILIPPE [FR] ET AL) 17 August 1993 (1993-08-17) cited in the application column 1, line 42 - line 68 column 2, line 1 - line 8 column 3, line 42 column 11, line 33 - line 34 -----	1-19

 Further documents are listed in the continuation of Box C. See patent family annex.

## \* Special categories of cited documents:

\*A\* document defining the general state of the art which is not considered to be of particular relevance

\*E\* earlier document but published on or after the international filing date

\*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

\*O\* document referring to an oral disclosure, use, exhibition or other means

\*P\* document published prior to the international filing date but later than the priority date claimed

\*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

\*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

\*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

\*G\* document member of the same patent family

Date of the actual completion of the international search

19 December 2007

Date of mailing of the international search report

03/01/2008

Name and mailing address of the ISA/

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Terenzi, Carla

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/US2007/074603

Patent document cited in search report	A	Publication date		Patent family member(s)	Publication date
US 5242950	A	07-09-1993		AT 175348 T	15-01-1999
				AU 679679 B2	10-07-1997
				AU 4033993 A	29-11-1993
				BR 9306283 A	30-06-1998
				DE 69322957 D1	18-02-1999
				DE 69322957 T2	01-07-1999
				DK 637238 T3	30-08-1999
				EP 0637238 A1	08-02-1995
				ES 2127819 T3	01-05-1999
				GR 3029670 T3	30-06-1999
				HU 72295 A2	29-04-1996
				JP 2669721 B2	29-10-1997
				JP 7505906 T	29-06-1995
				NO 944018 A	21-10-1994
				WO 9321894 A2	11-11-1993
<hr style="border-top: 1px dashed black;"/>					
US 5236957	A	17-08-1993		AU 645752 B2	27-01-1994
				AU 5729990 A	18-12-1990
				CA 2033190 A1	26-11-1990
				CN 1047496 A	05-12-1990
				CZ 9002520 A3	12-06-1996
				DE 69004337 D1	09-12-1993
				DE 69004337 T2	24-02-1994
				DK 400495 T3	06-12-1993
				WO 9014334 A1	29-11-1990
				EP 0400495 A1	05-12-1990
				EP 0426816 A1	15-05-1991
				ES 2062174 T3	16-12-1994
				FI 114792 B1	31-12-2004
				HU 55348 A2	28-05-1991
				HU 9500703 A3	28-12-1995
				IE 63934 B1	28-06-1995
				IL 94466 A	24-01-1995
				JP 2771328 B2	02-07-1998
				JP 4500215 T	16-01-1992
				NO 910270 A	23-01-1991
	NZ 233785 A	23-12-1992			
	PT 94160 A	08-01-1991			